Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance

16 Dec 2014

Abstract excerpt

Pan- or multidrug resistance is a central problem in clinical oncology. Here, we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP inhibition. We found that multidrug resistance was strongly associated with an EMT-like sarcomatoid phenotype and high expression of the Abcb1b gene, which encodes the drug efflux...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Genomics and Chromatin Dynamics
Share to Metastasis and carcinoma case studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25511378
DOI: 10.1158/0008-5472.can-14-0839

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug ResistancePMID 25511378Read ↗

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancerSemantic proximity Read ↗

What Makes Tumors Multidrug Resistant?Semantic proximity Read ↗

Drug resistance in the mouse cancer clinicSemantic proximity Read ↗

Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor TopotecanSemantic proximity Read ↗

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.Semantic proximity Read ↗

Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast CancerSemantic proximity Read ↗

Establishment and characterization of a multi-drug resistant cell line for canine mammary tumorsSemantic proximity Read ↗

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.Semantic proximity Read ↗

Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug ResistanceSemantic proximity Read ↗

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?Semantic proximity Read ↗

From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapiesSemantic proximity Read ↗

Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.